Neuroendocrine Tumors
Conditions
Brief summary
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Interventions
DIAGNOSTIC_TEST18F-AlF-NOTA-Octreotide PET-CT or PET-MR
18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging
Sponsors
First Affiliated Hospital of Zhejiang University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosed of neuroendocrine neoplasms. 2. Suspected of neuroendocrine neoplasms.
Exclusion criteria
1. Inability to undergo biopsy/surgical treatment. 2. Concurrent active malignancy. 3. Severe uncontrolled comorbidities/active infections. 4. Inability to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic efficacy | through study completion, an average of 1.5 year | Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms |
Other
| Measure | Time frame | Description |
|---|---|---|
| Prognostic Value of Baseline 18F-OC PET for Progression-Free Survival (PFS) in High-Risk Patients | through study completion, 3-4 years | This measure evaluates the association between baseline 18F-OC PET parameters (e.g., SUVmax, SUVmean, metabolic tumor volume \[MTV\], total lesion glycolysis \[TLG\]) and progression-free survival (PFS) in high-risk neuroendocrine neoplasms patients. PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model. |
Contacts
Primary ContactDonghe Chen
Outcome results
None listed